A
Asieris Pharmaceuticals
A global pharma company specializing in new drugs for the treatment of genitourinary tumors and other major diseases
About Asieris Pharmaceuticals
Asieris Pharmaceuticals was founded by Kevin Pan in March 2010, in China Medical City, Jiangsu Taizhou. The company has been at the forefront of developing innovative treatments for genitourinary tumors and related diseases. With a strong commitment to research and development, Asieris has positioned itself as a leader in this specialized field.
In its journey, Asieris Pharmaceuticals achieved a significant milestone by going public. On January 7, 2022, the company launched its Initial Public Offering (IPO) on the Shanghai Stock Exchange's STAR Market, opening with a stock price of CN¥22.98. This event marked a new chapter in Asieris's growth, providing the company with the capital needed to expand its research capabilities and global reach.
Prior to its IPO, Asieris had successfully secured funding from a variety of investors, including a notable Series D financing round led by Qiming Venture Partners in 2020. This financial backing was crucial in supporting the company's ambitious research projects and commercialization strategies.
Today, Asieris Pharmaceuticals continues to innovate in the field of cancer treatment, leveraging its strong foundation in research and development to bring new therapies to market. The company's journey from a startup to a publicly traded entity underscores its dedication to improving patient outcomes and advancing medical science.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2010
- Headquarters
- Pudong, China
- Employees
- 60
- Open positions
- None listed
- Dealroom signal
- 73.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Jul 2022
- Capital deployed
- $0
- Preferred round
- SERIES A
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Nov 2020 | $96M | $385M | CICC · Qiming Venture Partners · Gopher Asset Management · V-Capital | ↗ |
| SERIES COther financing | Mar 2020 | $14M | $56M | Kaitai Capital · Lapam Capital · Efund Capital · Shenzhen Guozhong Venture Capital Management | ↗ |
Growth signals
Latest recorded traffic for Asieris Pharmaceuticals is 3.4K monthly website visits, up 25.9% over the last three months. Asieris Pharmaceuticals's team grew 5.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later16 investors entered at this stage
- KCKaitai Capital
Lapam Capital- ECEfund Capital
Shenzhen Guozhong Venture Capital Management
CICC
Qiming Venture Partners
Gopher Asset Management
V-Capital- TCTriWise Capital
- IFIFSC
YunFeng Capital
SAIC Investment- ICIn Capital
Xiamen C&D- SMShanghai Hongxin Equity Investment Fund Management
- HFHaoshuo Zhier Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Asieris Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Asieris Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.